TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody aims to clean heart of sticky proteins
Disease control Recruiting nowThis early-stage study tests a new medicine called coramitug in 14 people with ATTR-CM, a heart condition caused by abnormal protein deposits. The drug is designed to bind to and help remove these deposits from the heart. Researchers will use special PET/CT scans to see where the…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 17, 2026 15:27 UTC
-
Could a new drug boost heart health in patients switching from standard therapy?
Disease control Recruiting nowThis study looks at whether switching from tafamidis to acoramidis can increase blood levels of a key protein (TTR) in adults with a heart condition called ATTR-CM. The condition happens when a protein breaks down and clogs the heart. About 50 people who have been on tafamidis fo…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Phase: PHASE4 • Sponsor: Bayer • Aim: Disease control
Last updated May 12, 2026 13:40 UTC